万古霉素浸泡在初次前交叉韧带重建感染预防中极具成本效益:一项成本效益研究
该经济与决策分析采用马尔可夫模型,比较万古霉素浸泡联合静脉抗生素预防与单独静脉抗生素预防在初次前交叉韧带重建(ACLR)中的成本效益。重复Meta分析纳入9项队列研究(3级证据),万古霉素浸泡预计每例患者节省660美元(美国)、581澳元(澳大利亚)、226欧元(西班牙),质量调整生命年提高0.007(4.297 vs 4.290)。若单独静脉抗生素的感染率低于0.014%,该技术将不再具有成本效益。
要点
- 万古霉素浸泡在初次ACLR中预防术后感染具有成本效益。
- 预计每例患者节省660美元(美国)、581澳元(澳大利亚)、226欧元(西班牙)。
- 若单独静脉抗生素感染率低于0.014%,万古霉素浸泡不再具有成本效益。
核心结论
- 万古霉素预浸泡技术是预防初次ACLR术后化脓性关节炎的一种极具成本效益的方法。
研究设计与样本
- 经济与决策分析,证据等级2。
- 采用马尔可夫模型比较万古霉素预浸泡联合静脉抗生素预防与单独静脉抗生素预防的成本效益。
- 重复检索PubMed、SCOPUS和Cochrane中央对照试验注册库,采用近期Meta分析的相同标准。
- 对9项队列研究(3级证据)进行重复Meta分析,确定万古霉素预浸泡相比单独静脉抗生素的感染比值比。
- 万古霉素技术、感染治疗和进一步手术的估计成本来源于当地医院和文献;进一步手术(包括翻修重建和初次关节置换)的转移概率来源于文献。
主要发现
- 万古霉素浸泡技术预计每例患者节省660美元(美国)、581澳元(澳大利亚)和226欧元(西班牙)。
- 与单独静脉抗生素预防相比,质量调整生命年提高0.007(4.297 vs 4.290)。
- 若单独静脉抗生素的感染率低于0.014%,万古霉素浸泡将不再具有成本效益。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although presoaking grafts in vancomycin has been demonstrated to be effective in observational studies for anterior cruciate ligament reconstruction (ACLR) infection prevention, the economic benefit of the technique is uncertain. PURPOSE: To 1) determine the cost-effectiveness of vancomycin presoaking during primary ACLR to prevent postoperative joint infections and 2) to establish the break-even cost-effectiveness threshold of the technique and determine its cost-effectiveness across various international health care settings. STUDY DESIGN: Economic and decision analysis; Level of evidence, 2. METHODS: A Markov model was used to determine cost-effectiveness and the incremental cost-effectiveness ratio of additional vancomycin presoaking compared with intravenous antibiotic prophylaxis alone. A repeated search of the PubMed, SCOPUS, and Cochrane Central Register of Controlled Trials databases, using the same criteria as a recent meta-analysis, was completed. A repeated meta-analysis of 9 cohort studies (level 3 evidence) was completed to determine the odds ratio of infection with vancomycin presoaking compared with intravenous antibiotics alone. Estimated costs of the vancomycin technique, treatment of infection, and further surgery were sourced from local hospitals and literature. Transitional probabilities for further surgery, including revision reconstruction and primary arthroplasty, were obtained from the literature. Probabilistic sensitivity analyses and a 1-way sensitivity analysis were performed to evaluate the ACLR infection rate break-even threshold for which the vancomycin technique would be no longer cost-effective. RESULTS: The vancomycin soaking technique provides expected cost savings of $660 (USA), A$581 (Australia), and €226 (Spain) per patient. There was an improvement in the quality-adjusted life-years of 0.007 compared with intravenous antibiotic prophylaxis alone (4.297 vs 4.290). If the infection rate is below 0.014% with intravenous antibiotics alone, the vancomycin wrap would no longer be cost-effective. CONCLUSION: The vancomycin presoaking technique is a highly cost-effective method to prevent postoperative septic arthritis after primary ACLR.
引用
- Truong AP, Pérez-Prieto D, Byrnes J, et al. Vancomycin Soaking Is Highly Cost-Effective in Primary ACLR Infection Prevention: A Cost-Effectiveness Study. Am J Sports Med. 2022. PMID: 35180008. doi:10.1177/03635465211073338
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。